Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

By Veltkamp Stephan A.  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 839-851

Adis International

Access to resources Recommend Favorite

Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 3, 2014-04 ,pp. : 447-451

Bentham Science Publishers

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M   Younk Lisa M   Davis Stephen N  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 3, 2015-03 ,pp. : 226-236

John Wiley & Sons Inc

Access to resources Recommend Favorite